No headlines found.
PRNewswire (Wed, 11-Feb 5:31 PM ET)
Business Wire (Tue, 10-Feb 8:45 AM ET)
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Business Wire (Tue, 20-Jan 8:00 AM ET)
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Lantern Pharma trades on the NASDAQ stock market under the symbol LTRN.
As of March 10, 2026, LTRN stock price declined to $2.72 with 2,101 million shares trading.
LTRN has a beta of 0.86, meaning it tends to be less sensitive to market movements. LTRN has a correlation of 0.05 to the broad based SPY ETF.
LTRN has a market cap of $30.42 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, LTRN traded as high as $11.99 and as low as $2.38.
The top ETF exchange traded funds that LTRN belongs to (by Net Assets): VTI, VXF, MEDX, IWC, DFSU.
LTRN has underperformed the market in the last year with a return of -25.7%, while the SPY ETF gained +18.9%. In the last 3 month period, LTRN fell short of the market, returning -29.9%, while SPY returned -0.5%. However, in the most recent 2 weeks LTRN has outperformed the stock market by returning +6.3%, while SPY returned -0.7%.
LTRN support price is $2.58 and resistance is $2.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LTRN shares will trade within this expected range on the day.